viewe-Therapeutics PLC

e-Therapeutics starts Phase IIb drug trial


AIM-listed biotechnology firm e-Therapeutics (LON: ETX) said it has started a Phase IIb trial of its ETS6103 drug, a controlled-release formulation of pain-reliever tramadol, for use in major depressive disorders.

e-Therapeutics said if the trial is positive, it intends to seek a licensing deal for the drug.

The randomised double-blind controlled trial, being conducted in the Glasgow area of Scotland with around 160 patients, is evaluating ETS6103 as a second-line treatment for patients who have not responded adequately to first-line therapy with an SSRI (selective serotonin reuptake inhibitor). It is being conducted by a group of primary care centres with a history of involvement in depression studies.

“We believe that ETS6103 has potential in this population and are working with an experienced group of clinicians to test this proposition in a randomised controlled trial,” Stephen Self, development director at e-Therapeutics, said.

e-Therapeutics expects to report the results of the trial in the first half of 2015.

Quick facts: e-Therapeutics PLC

Price: 12 GBX

Market: AIM
Market Cap: £38.69 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics PLC named herein, including the promotion by the Company of e-Therapeutics PLC in any Content on the Site, the Company receives...


2 min read